WO2021117697A1 - 固形製剤 - Google Patents
固形製剤 Download PDFInfo
- Publication number
- WO2021117697A1 WO2021117697A1 PCT/JP2020/045562 JP2020045562W WO2021117697A1 WO 2021117697 A1 WO2021117697 A1 WO 2021117697A1 JP 2020045562 W JP2020045562 W JP 2020045562W WO 2021117697 A1 WO2021117697 A1 WO 2021117697A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- solid preparation
- preparation according
- cellulose
- dotinurad
- Prior art date
Links
- 239000007787 solid Substances 0.000 title claims abstract description 69
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract description 4
- 238000002360 preparation method Methods 0.000 claims abstract description 72
- VOFLAIHEELWYGO-UHFFFAOYSA-N (3,5-dichloro-4-hydroxyphenyl)-(1,1-dioxo-2h-1,3-benzothiazol-3-yl)methanone Chemical compound C1=C(Cl)C(O)=C(Cl)C=C1C(=O)N1C2=CC=CC=C2S(=O)(=O)C1 VOFLAIHEELWYGO-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229920002678 cellulose Polymers 0.000 claims abstract description 20
- 239000001913 cellulose Substances 0.000 claims abstract description 20
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 150000005846 sugar alcohols Chemical class 0.000 claims abstract description 7
- 229940069601 dotinurad Drugs 0.000 claims description 29
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 28
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 22
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 17
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 17
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 15
- 229950008138 carmellose Drugs 0.000 claims description 15
- 235000019359 magnesium stearate Nutrition 0.000 claims description 14
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 12
- -1 sucrose fatty acid ester Chemical class 0.000 claims description 12
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 11
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 11
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 11
- 235000010355 mannitol Nutrition 0.000 claims description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 229920000881 Modified starch Polymers 0.000 claims description 8
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 8
- 229960003943 hypromellose Drugs 0.000 claims description 8
- 239000000454 talc Substances 0.000 claims description 8
- 229910052623 talc Inorganic materials 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 7
- 239000007884 disintegrant Substances 0.000 claims description 7
- 239000000314 lubricant Substances 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 229920002261 Corn starch Polymers 0.000 claims description 5
- 239000008120 corn starch Substances 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 claims description 4
- 229940063655 aluminum stearate Drugs 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 4
- 239000008116 calcium stearate Substances 0.000 claims description 4
- 235000013539 calcium stearate Nutrition 0.000 claims description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000000395 magnesium oxide Substances 0.000 claims description 4
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 4
- 235000012245 magnesium oxide Nutrition 0.000 claims description 4
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 235000010981 methylcellulose Nutrition 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 239000008117 stearic acid Substances 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 3
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000008187 granular material Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000000654 additive Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 229910001220 stainless steel Inorganic materials 0.000 description 5
- 239000010935 stainless steel Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 241000278713 Theora Species 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 238000000748 compression moulding Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- MCRNHLQVPJEMSQ-UHFFFAOYSA-N C(C=CC(=O)O)(=O)O.C(CCCCCCCCCCCCCCCCC)[Na] Chemical compound C(C=CC(=O)O)(=O)O.C(CCCCCCCCCCCCCCCCC)[Na] MCRNHLQVPJEMSQ-UHFFFAOYSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000003424 uricosuric effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Definitions
- the present invention relates to 3- (3,5-dichloro-4-hydroxybenzoyl) -1,1-dioxo-2,3-dihydro-1,3-benzothiazole represented by the following chemical structural formula [hereinafter, "dotinurad”. "(common name) or” (3,5-dichloro-4-hydroxyphenyl) (1,1-dioxo-1,2-dihydro-3H-1 [lambda 6-1,3-benzothiazol-3-yl) methanone " It may be described as] or a solid preparation containing a pharmacologically acceptable salt thereof as an active ingredient.
- Dotinrad is a promising compound as a therapeutic agent for gout and hyperuricemia because it has a remarkable uricosuric effect (Patent Document 1).
- the drug is a pharmaceutical composition in which additives such as excipients are appropriately added to the active ingredient, and further, a drug suitable for the administration route (for example, a solid drug, a liquid drug, etc.) is prepared and then provided and administered to the patient. Will be done. Therefore, in the pharmaceutical composition and the preparation, it is desirable that the active ingredient and the preparation itself are highly stable and easy to handle and take.
- Patent Document 1 discloses a pharmaceutical formulation example (tablet) containing dotinurad and composed of lactose, corn starch, hydroxypropyl cellulose and magnesium stearate.
- tablette a pharmaceutical formulation example
- An object of the present invention is to provide a solid preparation containing dotinrad as an active ingredient and having excellent stability and manufacturability.
- the present invention describes (1) 3- (3,5-dichloro-4-hydroxybenzoyl) -1,1-dioxo-2,3-dihydro-1,3-benzothiazole [dotinurad] or its pharmacologically.
- a solid preparation comprising an acceptable salt as an active ingredient and further containing a sugar alcohol, a cellulose derivative, or both as an excipient.
- the content of dotinurad or a pharmacologically acceptable salt thereof is 0.125% by weight or more and 2.0% by weight or less based on the total weight of the solid preparation.
- the solid preparation according to any one of (7). (9) The solid preparation according to any one of (1) to (8) above, which further contains a disintegrant, a binder, and a lubricant. (10) From the group consisting of carmellose, carmellose calcium, carmellose sodium, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, croscarmellose sodium, crystalline cellulose, carboxymethyl starch sodium, corn starch, and talc as disintegrants.
- the solid preparation according to (9) above which comprises one or more selected species.
- the binder comprises one or more selected from the group consisting of low-degree-of-substitution hydroxypropyl cellulose, hypromellose, methyl cellulose, polyvinyl alcohol, partially pregelatinized starch, and pregelatinized starch.
- the lubricant contains at least one selected from the group consisting of magnesium oxide, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, sucrose fatty acid ester, sodium stearyl fumarate, and talc.
- the solid preparation according to any one of (9) to (11) above, which comprises the above.
- the solid preparation of the present invention is characterized in that the decomposition of the main agent (active ingredient) is suppressed and the stability is high.
- the present invention provides a solid preparation containing dotinurad or a pharmacologically acceptable salt thereof as an active ingredient.
- the solid preparation contains 0.125% by weight or more and 2.0% by weight or less of dotinrad as an active ingredient with respect to the total weight.
- dotinurad when used, its hydrate and solvate are also included.
- the pharmacologically acceptable salt of dotinurad is not particularly limited as long as it is a pharmaceutically acceptable salt, and examples thereof include alkali metal salts and alkaline earth metal salts, and hydration thereof. Includes products and solvates.
- the dose of dotinurad or a pharmacologically acceptable salt thereof per dose to humans is preferably 0.1 mg to 4.0 mg.
- the solid preparation of the present invention contains D-mannitol as an excipient in an amount of 10% by weight or more and 50% by weight or less, preferably 25% by weight or more and 50% by weight or less, based on the total weight of the solid preparation.
- the solid preparation of the present invention preferably contains crystalline cellulose in an amount of 5% by weight or more and 30% by weight or less based on the total weight of the solid preparation.
- the solid preparation of the present invention preferably contains lactose hydrate in an amount of 25% by weight or more and 70% by weight or less based on the total weight of the solid preparation.
- the solid preparation of the present invention preferably contains carmellose in an amount of 3% by weight or more and 7% by weight or less based on the total weight of the solid preparation.
- the solid preparation of the present invention preferably contains hypromellose in an amount of 1% by weight or more and 5% by weight or less based on the total weight of the solid preparation.
- the solid preparation of the present invention preferably contains magnesium stearate in an amount of 0.25% by weight or more and 1% by weight or less based on the total weight of the solid preparation.
- the value of% by weight of dotinurad and the additive may include a value up to ⁇ 10% of the value, preferably up to ⁇ 5% of the value.
- the disintegrant in the present invention is not particularly limited, but is preferably approved as a pharmaceutical additive component, and preferred examples include carmellose (carboxymethyl cellulose), carmellose calcium, carmellose sodium, hydroxypropyl cellulose, and low degree of substitution hydroxy. Examples thereof include propyl cellulose, croscarmellose sodium, crystalline cellulose, carboxymethyl starch sodium, crospopidone, corn starch, talc and the like, which can be used alone or in combination as appropriate.
- carmellose (carboxymethyl cellulose), carmellose calcium, carmellose sodium, hydroxypropyl cellulose, low degree of substitution hydroxypropyl cellulose, croscarmellose sodium, crystalline cellulose, carboxymethyl starch sodium, corn starch, and talc. Particularly preferred is carmellose.
- the binder in the present invention is not particularly limited, but those approved as pharmaceutical additive components are preferable, and preferred examples thereof include low-degree-of-substitution hydroxypropyl cellulose, hydroxypropyl cellulose, hypromellose (hydroxypropyl methyl cellulose), methyl cellulose, popidone, and the like.
- Examples thereof include polyvinyl alcohol, partially pregelatinized starch, pregelatinized starch and the like. Hydroxypropyl cellulose with a low degree of substitution, hypromellose (hydroxypropyl methyl cellulose), methyl cellulose, polyvinyl alcohol, partially pregelatinized starch, and pregelatinized starch are preferable, and hypromellose is particularly preferable.
- the lubricant in the present invention is not particularly limited, but those approved as pharmaceutical additive components are preferable, and preferred examples thereof include magnesium silicate, magnesium oxide, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, and the like. Examples thereof include magnesium aluminometasilicate, sucrose fatty acid ester, stearyl sodium fumarate, and talc. Preferred examples include magnesium oxide, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, sucrose fatty acid ester, sodium stearyl fumarate, and talc, and magnesium stearate is particularly preferable.
- the solid preparation in the present invention includes, for example, tablets (including uncoated tablets, sugar-coated tablets, orally rapidly disintegrating tablets, chewable agents, effervescent tablets, troches, film-coated tablets, etc.), pills, powders, powders, fine granules.
- tablets including uncoated tablets, sugar-coated tablets, orally rapidly disintegrating tablets, chewable agents, effervescent tablets, troches, film-coated tablets, etc.
- pills powders, powders, fine granules.
- examples thereof include agents, granules, hard capsules, soft capsules, films, dry syrups, jellies, liquids, emulsions, syrups, injections, external preparations, suppositories, etc., preferably tablets or granules. Particularly preferably, it is a tablet.
- the weight per tablet is not particularly limited, but is preferably 50 mg to 500 mg. Further, 100 mg to 200 mg is more preferable.
- various additives can be used according to the applicable preparation.
- disintegrant aids fluidizers, buffers, sustainers, stabilizers, antioxidants, reducing agents, cooling agents, etc.
- Sweeteners, flavoring agents, fragrances, colorants, surfactants, reversible agents, solubilizers, suspending agents, dispersants, emulsifiers, buffers, solubilizers, brighteners, coating agents, bases, preservatives , Preservatives, pH adjusters and the like can be used.
- dotinurad or a pharmaceutically acceptable salt thereof is 0.125% by weight to 2.0% by weight, and lactose hydrate is 49% by weight or more, based on the total weight of the solid preparation. 54% by weight, D-mannitol 24% to 26% by weight, crystalline cellulose 14% to 16% by weight, carmellose 3% to 7% by weight, hypromerose 1% to 5% by weight, magnesium stearate To provide a solid preparation containing 0.25% by weight to 1% by weight of.
- the water content indicates the result of measuring the water content contained in the solid preparation containing dotinurad as an active ingredient with an infrared moisture meter (FD-620 manufactured by Ketsuto Scientific Research Institute). (75 ° C., 20 minutes). Further, in the specification of the present application, the water content (after drying) is the result of measuring the water content contained in the formulation by the method described above after mixing, granulating and drying dotinrad and the additive.
- FD-620 infrared moisture meter manufactured by Ketsuto Scientific Research Institute
- the component content indicates the ratio (%) of the amount of the active ingredient contained in the actually manufactured tablet to the theoretically calculated content of the active ingredient.
- the component content is preferably 95% to 110%, more preferably 97 to 105%. Further, in the present specification, a case where the component content is less than 95% is described as a decrease.
- Example 1 8.0 g of lactose hydrate (DMV, family 200M) and 0.8 g of dotinurad were sieved using a No. 30 stainless steel sieve.
- Granules are granulated with a stirring granulator (Fukae Kogyo, High Speed Mixer LFS-GS-1JD) using 31.8 g of purified water, air-dried at 60 ° C. for 240 minutes, and trimmed using a No. 30 stainless steel sieve. Granulated to obtain granules. To this, 1.6 g of magnesium stearate (NOF, Magnesium stearate) was added and mixed.
- a stirring granulator Fukae Kogyo, High Speed Mixer LFS-GS-1JD
- Example 2 8.0 g of lactose hydrate (DMV, family 200M) and 0.8 g of dotinurad were sieved using a No. 30 stainless steel sieve.
- Lactose hydrate (DMV, farmose200M) 156.0 g
- D-mannitol (rocket, pairitol 50C) 80.0 g
- Granules are granulated with a stirring granulator (Fukae Kogyo, High Speed Mixer LFS-GS-1JD) using 31.8 g of purified water, air-dried at 60 ° C. for 240 minutes, and trimmed using a No. 30 stainless steel sieve. Granulated to obtain granules. To this, 1.6 g of magnesium stearate (NOF, Magnesium stearate) was added and mixed.
- a stirring granulator Fukae Kogyo, High Speed Mixer LFS-GS-1JD
- Examples 3 to 17 and Reference Examples produced tablets in the same manner as in Examples 1 and 2 based on the formulations shown in Tables 1 to 3.
- Tables 1 to 4 show the formulation ratio, manufacturability, water content (after drying), and component content of the tablets produced in Examples, Reference Examples, and Comparative Examples.
- Example 4 The tablet stability tests were carried out in the form of the tablets obtained in Example 4 and Comparative Example 1 in a blister-packed form under an atmosphere of 40 ° C. ⁇ 2 ° C. and 75% RH ⁇ 5% RH.
- High performance liquid chromatography (column: acetonitrile ODS-2 (4.6)) was used to determine the amount (%) of dotinurad-related substances in tablets at the start of the test, 1 month after the start, and 3 months after the start of the test.
- temperature 40 ° C. mobile phase: diluted formic acid (1 ⁇ 1000) / acetonitrile mixed solution (3: 2), UV detection: 240 nm).
- Table 5 The results are shown in Table 5.
- Example 4 and Comparative Examples 1 and 2 had a total exposure of 1.2 million lux hours and 200 watt hours / m2 or more at 25 ° C ⁇ 2 ° C under a light source emitting visible light and UV-A light.
- a light stability test was carried out under light-shielding or light-exposed conditions for 20 days.
- the amount (%) of dotinurad-related substances in tablets at the start of the test, at the time of shading, and at the time of exposure was determined by high performance liquid chromatography (column: acetonitrile ODS-2 (4.6 mm ⁇ 250 mm, 5 ⁇ m), temperature. Calculated using 40 ° C., mobile phase: diluted formic acid (1 ⁇ 1000) / acetonitrile mixed solution (3: 2), UV detection: 240 nm). The results are shown in Table 7.
- Examples 1 and 2 having a low D-mannitol content adhesion to manufacturing equipment was confirmed. Further, in Reference Example 1 having a high D-mannitol content, a decrease in the component content of dotinurad was confirmed. From the above results, it was found that the preferable D-mannitol content in the formulation is 10% by weight to 50% by weight.
- Example 4 From the results shown in Tables 5 and 6, it was confirmed that the production of related substances was suppressed in Example 4 as compared with Comparative Examples 1 and 2, and the pharmaceutical product was more stable.
- Comparative Examples 1 and 2 it is considered that the high water content (after drying) in the formulation affected the stability of the formulation.
- all of the above-described examples have a lower water content (after drying) than Comparative Examples 1 and 2, suggesting that they are stable formulations as in Example 4.
- Example 4 suppressed the production of dotsinurad-related substances as compared with Comparative Examples 1 and 2, and was a more stable preparation.
- the solid preparation of the present invention containing dotinrad or a pharmacologically acceptable salt thereof as an active ingredient and containing D-mannitol has high preparation stability and a decrease in the content of dotinurad.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
(1)3-(3,5-ジクロロ-4-ヒドロキシベンゾイル)-1,1-ジオキソ-2,3-ジヒドロ-1,3-ベンゾチアゾール[ドチヌラド]又はその薬理学的に許容される塩を有効成分として含有し、更に賦形剤として糖アルコール又はセルロース誘導体、あるいはそれらの両方を含むことを特徴とする固形製剤。
(2)糖アルコールの含有量が、固形製剤の総重量に対し10重量%以上50重量%以下であることを特徴とする前記(1)に記載の固形製剤。
(3)前記糖アルコールがD-マンニトールであることを特徴とする前記(1)または(2)に記載の固形製剤。
(4)セルロース誘導体の含有量が、固形製剤の総重量に対し5重量%以上30重量%以下であることを特徴とする前記(1)-(3)のいずれかに記載の固形製剤。
(5)前記セルロース誘導体が結晶セルロースであることを特徴とする前記(1)-(4)のいずれかに記載の固形製剤。
(6)更に賦形剤として、乳糖水和物を含有することを特徴とする前記(1)-(5)のいずれかに記載の固形製剤。
(7)前記乳糖水和物の含有量が、固形製剤の総重量に対し25重量%以上70重量%以下であることを特徴とする前記(6)に記載の固形製剤。
(8)ドチヌラド又はその薬理学的に許容される塩の含有量が、固形製剤の総重量に対し0.125重量%以上2.0重量%以下であることを特徴とする前記(1)-(7)のいずれかに記載の固形製剤。
(9)更に崩壊剤、結合剤、及び滑沢剤を含有することを特徴とする前記(1)-(8)のいずれかに記載の固形製剤。
(10)崩壊剤として、カルメロース、カルメロースカルシウム、カルメロースナトリウム、ヒドロキシプロピルセルロース、低置換度ヒドロキシプロピルセルロース、クロスカルメロースナトリウム、結晶セルロース、カルボキシメチルスターチナトリウム、トウモロコシデンプン、及びタルクからなる群より選ばれる1種以上を含むことを特徴とする、前記(9)に記載の固形製剤。
(11)結合剤として、低置換度ヒドロキシプロピルセルロース、ヒプロメロース、メチルセルロース、ポリビニルアルコール、部分アルファ化デンプン、及びアルファ化デンプンからなる群より選ばれる1種以上を含むことを特徴とする、前記(9)又は(10)に記載の固形製剤。
(12)滑沢剤として、酸化マグネシウム、ステアリン酸、ステアリン酸マグネシウム、ステアリン酸アルミニウム、ステアリン酸カルシウム、ショ糖脂肪酸エステル、フマル酸ステアリルナトリウム、及びタルク、よりなる群より選ばれる1種以上を含むことを特徴とする、前記(9)-(11)のいずれかに記載の固形製剤。
(13)ドチヌラド又はその薬理学的に許容される塩を有効成分として含む固形製剤であって、当該固形製剤の総重量に対し、ドチヌラド又はその薬理学的に許容される塩を0.125重量%~2.0重量%、乳糖水和物を25重量%~70重量%、D-マンニトールを10重量%~50重量%、結晶セルロースを5重量%~30重量%、カルメロースを3重量%~7重量%、ヒプロメロースを1重量%~5重量%、及びステアリン酸マグネシウムを0.25重量%~1重量%含有することを特徴とする固形製剤。
(14)錠剤であることを特徴とする前記(1)-(13)のいずれかに記載の固形製剤。
++:製造時における固形製剤の取扱が良である
+ :製造時における固形製剤の取扱が可である。
ただし、取扱が良とは製造機器への付着が起こらない場合を示し、取扱が可とは製造機器への付着が認められた場合を示す。
Claims (14)
- 3-(3,5-ジクロロ-4-ヒドロキシベンゾイル)-1,1-ジオキソ-2,3-ジヒドロ-1,3-ベンゾチアゾール[ドチヌラド]又はその薬理学的に許容される塩を有効成分として含有し、更に、賦形剤として糖アルコール又はセルロース誘導体、あるいはそれらの両方を含むことを特徴とする固形製剤。
- 糖アルコールの含有量が、固形製剤の総重量に対し10重量%以上50重量%以下であることを特徴とする請求項1に記載の固形製剤。
- 前記糖アルコールがD-マンニトールであることを特徴とする請求項1または請求項2に記載の固形製剤。
- セルロース誘導体の含有量が、固形製剤の総重量に対し5重量%以上30重量%以下であることを特徴とする請求項1ないし請求項3のいずれか1項に記載の固形製剤。
- 前記セルロース誘導体が結晶セルロースであることを特徴とする請求項1ないし請求項4のいずれか1項に記載の固形製剤。
- 更に賦形剤として、乳糖水和物を含有することを特徴とする請求項1ないし請求項5のいずれか1項に記載の固形製剤。
- 前記乳糖水和物の含有量が、固形製剤の総重量に対し25重量%以上70重量%以下であることを特徴とする請求項6に記載の固形製剤。
- ドチヌラド又はその薬理学的に許容される塩の含有量が、固形製剤の総重量に対し0.125重量%以上2.0重量%以下であることを特徴とする請求項1ないし請求項7のいずれか1項に記載の固形製剤。
- 更に崩壊剤、結合剤、及び滑沢剤を含有することを特徴とする請求項1ないし請求項8のいずれか1項に記載の固形製剤。
- 崩壊剤として、カルメロース、カルメロースカルシウム、カルメロースナトリウム、ヒドロキシプロピルセルロース、低置換度ヒドロキシプロピルセルロース、クロスカルメロースナトリウム、結晶セルロース、カルボキシメチルスターチナトリウム、トウモロコシデンプン、及びタルクからなる群より選ばれる1種以上を含むことを特徴とする請求項9に記載の固形製剤。
- 結合剤として、低置換度ヒドロキシプロピルセルロース、ヒプロメロース、メチルセルロース、ポリビニルアルコール、部分アルファ化デンプン、及びアルファ化デンプンからなる群より選ばれる1種以上を含むことを特徴とする請求項9又は10に記載の固形製剤。
- 滑沢剤として、酸化マグネシウム、ステアリン酸、ステアリン酸マグネシウム、ステアリン酸アルミニウム、ステアリン酸カルシウム、ショ糖脂肪酸エステル、フマル酸ステアリルナトリウム、及びタルクからなる群より選ばれる1種以上を含むことを特徴とする請求項9ないし請求項11のいずれか1項に記載の固形製剤。
- ドチヌラド又はその薬理学的に許容される塩を有効成分として含む固形製剤であって、当該固形製剤の総重量に対し、ドチヌラド又はその薬理学的に許容される塩を0.125重量%~2.0重量%、乳糖水和物を25重量%~70重量%、D-マンニトールを10重量%~50重量%、結晶セルロースを5重量%~30重量%、カルメロースを3重量%~7重量%、ヒプロメロースを1重量%~5重量%、及びステアリン酸マグネシウムを0.25重量%~1重量%含有することを特徴とする固形製剤。
- 錠剤であることを特徴とする請求項1ないし請求項13のいずれか1項に記載の固形製剤。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3159300A CA3159300A1 (en) | 2019-12-09 | 2020-12-08 | Solid pharmaceutical preparation |
US17/756,978 US20230050931A1 (en) | 2019-12-09 | 2020-12-08 | Solid pharmaceutical preparation |
EP20900113.0A EP4074313A4 (en) | 2019-12-09 | 2020-12-08 | SOLID PHARMACEUTICAL PREPARATION |
JP2021563960A JP7355846B2 (ja) | 2019-12-09 | 2020-12-08 | 固形製剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019221892 | 2019-12-09 | ||
JP2019-221892 | 2019-12-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021117697A1 true WO2021117697A1 (ja) | 2021-06-17 |
Family
ID=76329847
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2020/045562 WO2021117697A1 (ja) | 2019-12-09 | 2020-12-08 | 固形製剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230050931A1 (ja) |
EP (1) | EP4074313A4 (ja) |
JP (1) | JP7355846B2 (ja) |
CA (1) | CA3159300A1 (ja) |
WO (1) | WO2021117697A1 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5325065B2 (ja) | 1974-10-07 | 1978-07-25 | ||
JP2011074017A (ja) * | 2009-09-30 | 2011-04-14 | Fujiyakuhin Co Ltd | 新規フェノール誘導体 |
JP2017193539A (ja) * | 2016-04-15 | 2017-10-26 | 株式会社富士薬品 | 併用療法剤 |
WO2018199277A1 (ja) * | 2017-04-28 | 2018-11-01 | 株式会社富士薬品 | 3-(3,5-ジクロロ-4-ヒドロキシベンゾイル)-1,1-ジオキソ-2,3-ジヒドロ-1,3-ベンゾチアゾールの結晶形及び塩 |
-
2020
- 2020-12-08 WO PCT/JP2020/045562 patent/WO2021117697A1/ja unknown
- 2020-12-08 EP EP20900113.0A patent/EP4074313A4/en active Pending
- 2020-12-08 CA CA3159300A patent/CA3159300A1/en active Pending
- 2020-12-08 JP JP2021563960A patent/JP7355846B2/ja active Active
- 2020-12-08 US US17/756,978 patent/US20230050931A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5325065B2 (ja) | 1974-10-07 | 1978-07-25 | ||
JP2011074017A (ja) * | 2009-09-30 | 2011-04-14 | Fujiyakuhin Co Ltd | 新規フェノール誘導体 |
JP2017193539A (ja) * | 2016-04-15 | 2017-10-26 | 株式会社富士薬品 | 併用療法剤 |
WO2018199277A1 (ja) * | 2017-04-28 | 2018-11-01 | 株式会社富士薬品 | 3-(3,5-ジクロロ-4-ヒドロキシベンゾイル)-1,1-ジオキソ-2,3-ジヒドロ-1,3-ベンゾチアゾールの結晶形及び塩 |
Non-Patent Citations (3)
Title |
---|
MOTOKI KEISUKE, IGARASHI TAKAKO, OMURA KOICHI, NAKATANI HIROSHI, IWANAGA TAKASHI, TAMAI IKUMI, OHASHI TETSUO: "Pharmacokinetic/pharmacodynamic modeling and simulation of dotinurad, a novel uricosuric agent, in healthy volunteers", PHARMACOL. RES. PERSPECT., 26 November 2019 (2019-11-26), pages 1 - 8, XP055834392, DOI: doi.org/10.1002/prp2.533 * |
See also references of EP4074313A4 |
TANIGUCHI TETSUYA, ASHIZAWA NAOKI, MATSUMOTO KOJI, SAITO RYO, MOTOKI KEISUKE, SAKAI MIKU, CHIKAMATSU NORIKO, HAGIHARA CHIHARU, HAS: "Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor", J. PHARMACOL. EXP. THER., vol. 371, 1 August 2019 (2019-08-01), pages 162 - 170, XP055834391 * |
Also Published As
Publication number | Publication date |
---|---|
EP4074313A1 (en) | 2022-10-19 |
US20230050931A1 (en) | 2023-02-16 |
JPWO2021117697A1 (ja) | 2021-06-17 |
EP4074313A4 (en) | 2024-01-03 |
JP7355846B2 (ja) | 2023-10-03 |
CA3159300A1 (en) | 2021-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7988994B2 (en) | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients | |
RU2744432C2 (ru) | Фармацевтическая композиция, включающая ингибитор янус-киназы или его фармацевтически приемлемую соль | |
WO2008027600A2 (en) | Imatinib compositions | |
EP2964200B1 (en) | Formulations of organic compounds | |
JP7116277B2 (ja) | 顆粒剤、並びに錠剤及びその製造方法 | |
WO2011074660A1 (ja) | 溶出安定性製剤 | |
EP3437645B1 (en) | Film-coated tablet having high chemical stability of active ingredient | |
US20200289523A1 (en) | Fixed dosed pharmaceutical composition comprising amiodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension | |
KR100594606B1 (ko) | 속방성 경구 의약품 조성물 | |
KR20080096779A (ko) | 신규 필름 코팅정 | |
JP2001503734A (ja) | カリウム、ナトリウムおよびトリスオキサプロジン塩医薬組成物 | |
WO2021117697A1 (ja) | 固形製剤 | |
JPH1121236A (ja) | ロキソプロフェン・ナトリウム固形製剤 | |
JP2021518422A (ja) | レナリドミドを含む医薬組成物 | |
JP2006257068A (ja) | 高含量塩酸テルビナフィン錠剤およびその製造方法 | |
KR102330953B1 (ko) | 소듐-1-[6-(모르폴린-4-일)피리미딘-4-일]-4-(1h-1,2,3-트리아졸-1-일)-1h-피라졸-5-올레이트를 함유하는 제약 투여 형태 | |
DK2898886T3 (en) | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION WITH IMPROVED ELUTION AND / OR ABSORPTION | |
UA80270C2 (en) | Medicinal composition containing 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid | |
JPS6281309A (ja) | バルプロ酸ナトリウム徐放錠 | |
JP2015010046A (ja) | クロピドグレル乃至その塩含有錠剤及びその製造方法 | |
WO2024085821A1 (en) | Content uniformity of teriflunomid in pharmaceutical dosage forms | |
JP2013103924A (ja) | 結晶性アトルバスタチンカルシウム含有錠剤の製造方法 | |
JP2021070662A (ja) | レナリドミドを含む医薬組成物 | |
JP2008031183A (ja) | 速放性経口医薬組成物 | |
JP2011213606A (ja) | ドネペジルを含有する固形製剤の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20900113 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021563960 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3159300 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020900113 Country of ref document: EP Effective date: 20220711 |